Significant Decrease in the Incidence of Genital Warts in Young Danish Women After Implementation of a National Human Papillomavirus Vaccination Program

Baandrup, Louise; Blomberg, Maria; Dehlendorff, Christian; Sand, Carsten; Andersen, Klaus K.; Kjær, Susanne K.

doi:10.1097/olq.0b013e31827bd66b

Cited by 140 publications

(97 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Australia, the qHPV vaccination program has led to a significant reduction in HPV prevalence and genital warts, as well as high-grade cervical lesions in young women (9)(10)(11)(12)(13). Marked reductions in HPV prevalence and/or genital warts have also been observed in the United States, Sweden, and Denmark (8,(14)(15)(16)(17). Six years after licensure of the qHPV vaccine in Denmark, a reduced risk of cervical lesions has also been observed at the population level (18).…”

Section: Introductionmentioning

confidence: 87%

Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease

Joura

Ault

Bosch

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

143

118

View full text Add to dashboard Cite

Background: We estimated the prevalence and incidence of 14 human papillomavirus (HPV) types (6/11/ 16/18/31/33/35/39/45/51/52/56/58/59) in cervicovaginal swabs, and the attribution of these HPV types in cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS), using predefined algorithms that adjusted for multiple-type infected lesions.Methods: A total of 10,656 women ages 15 to 26 years and 1,858 women ages 24 to 45 years were enrolled in the placebo arms of one of three clinical trials of a quadrivalent HPV vaccine. We estimated the cumulative incidence of persistent infection and the proportion of CIN/AIS attributable to individual carcinogenic HPV genotypes, as well as the proportion of CIN/AIS lesions potentially preventable by a prophylactic 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine.Results: The cumulative incidence of persistent infection with !1 of the seven high-risk types included in the 9-valent vaccine was 29%, 12%, and 6% for women ages 15 to 26, 24 to 34, and 35 to 45 years, respectively. A total of 2,507 lesions were diagnosed as CIN or AIS by an expert pathology panel. After adjusting for multiple-type infected lesions, among women ages 15 to 45 years, these seven high-risk types were attributed to 43% to 55% of CIN1, 70% to 78% of CIN2, 85% to 91% of CIN3, and 95% to 100% of AIS lesions, respectively. The other tested types (HPV35/39/51/56/59) were attributed to 23% to 30% of CIN1, 7% to 14% of CIN2, 3% to 4% of CIN3, and 0% of AIS lesions, respectively.Conclusions: Approximately 85% or more of CIN3/AIS, >70% CIN2, and approximately 50% of CIN1 lesions worldwide are attributed to HPV6/11/16/18/31/33/45/52/58. Impact: If 9-valent HPV vaccination programs are effectively implemented, the majority of CIN2 and CIN3 lesions worldwide could be prevented, in addition to approximately one-half of CIN1. Cancer Epidemiol Biomarkers Prev; 23(10); 1997-2008. Ó2014 AACR.

show abstract

Section: Introductionmentioning

confidence: 87%

Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease

Joura

Ault

Bosch

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

143

118

View full text Add to dashboard Cite

show abstract

“…12 The quadrivalent HPV (6/11/16/18) virus-like particle (qHPV) vaccine is highly efficacious in preventing infection and cervical, vaginal, vulvar, and anal dysplasia caused by HPV 6/11/16/18 as well as HPV 6/11-related condyloma, [13][14][15][16] and the bivalent HPV (16/18) vaccine is highly efficacious against HPV 16/18-related infection and cervical dysplasia. 17 Postlicensure studies have shown a rapid decrease in the incidence of high-grade cervical abnormalities, [18][19][20][21] prevalence of vaccine HPV types, [22][23][24][25][26] and incidence of genital warts [27][28][29][30][31] in vaccinees. Data have shown that prophylactic HPV vaccination is generally safe and well tolerated.…”

Section: What This Study Addsmentioning

confidence: 99%

Immunogenicity and Safety of a 9-Valent HPV Vaccine

et al. 2015

View full text Add to dashboard Cite

OBJECTIVES: Prophylactic vaccination of youngwomen aged 16 to 26 years with the 9-valent (6/11/16/18/31/33/45/52/58) human papillomavirus (HPV) virus-like particle (9vHPV) vaccine prevents infection and disease. We conducted a noninferiority immunogenicity study to bridge the findings in young women to girls and boys aged 9 to 15 years.METHODS: Subjects (N = 3066) received a 3-dose regimen of 9vHPV vaccine administered at day 1, month 2, and month 6. Anti-HPV serologic assays were performed at day 1 and month 7. Noninferiority required that the lower bound of 2-sided 95% confidence intervals of geometric mean titer ratios (boys:young women or girls:young women) be .0.67 for each HPV type. Systemic and injection-site adverse experiences (AEs) and serious AEs were monitored.RESULTS: At 4 weeks after dose 3, .99% of girls, boys, and young women seroconverted for each vaccine HPV type. Increases in geometric mean titers to HPV types 6/11/16/18/ 31/33/45/52/58 were elicited in all vaccine groups. Responses in girls and boys were noninferior to those of young women. Persistence of anti-HPV responses was demonstrated through 2.5 years after dose 3. Administration of the 9vHPV vaccine was generally well tolerated. A lower proportion of girls (81.9%) and boys (72.8%) than young women (85.4%) reported injection-site AEs, most of which were mild to moderate in intensity.CONCLUSIONS: These data support bridging the efficacy findings with 9vHPV vaccine in young women 16 to 26 years of age to girls and boys 9 to 15 years of age and implementing genderneutral HPV vaccination programs in preadolescents and adolescents.WHAT'S KNOWN ON THIS SUBJECT: Prophylactic vaccination of young women 16 to 26 years of age with the 9-valent human papillomavirus (HPV)-like particle (9vHPV) vaccine prevents infection and disease with vaccine HPV types.WHAT THIS STUDY ADDS: These data support bridging the efficacy findings with 9vHPV vaccine in young women 16 to 26 years of age to girls and boys 9 to 15 years of age and implementation of gender-neutral HPV vaccination programs in preadolescents and adolescents.

show abstract

“…24 Our observed safety findings are also similar to that of other studies, whereby vaccine recipients have higher rates of injection site pain, erythema and swelling, but similar rates of systemic AEs. 32 Given the high vaccine efficacy seen in the clinical trials, and the fact that in the 8 y since its original licensure, the qHPV vaccine has been shown to be highly effective at the population level, with marked reductions in the prevalence of HPV vaccine-type related infection and disease in many countries, [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] our findings suggest the vaccine should be equally effective in sub-Saharan African women.…”

mentioning

confidence: 99%

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Mugo

Ansah

Marino

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Significant Decrease in the Incidence of Genital Warts in Young Danish Women After Implementation of a National Human Papillomavirus Vaccination Program

Abstract: The incidence of GWs decreased substantially among women with high HPV vaccine coverage, pointing to the effect of the national HPV vaccination program.

Cited by 140 publications

References 22 publications

Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease

Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease

Immunogenicity and Safety of a 9-Valent HPV Vaccine

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Contact Info

Product

Resources

About